Ilaris is an anti-inflammatory drug indicated for the treatment of autoimmune inflammatory diseases, such as multisystem inflammatory diseases or juvenile idiopathic arthritis, for example.
Its active substance is canaquinumab, a substance that inhibits the action of an important protein in inflammatory processes, thus controlling and relieving symptoms of inflammatory diseases in case of excessive production of this protein.
- Ilaris is a drug produced by Novartis Laboratories that can only be administered in the hospital and is therefore not available in pharmacies.
Treatment with Ilaris is priced at approximately 60,000 reais for each 150 mg vial, however, in most cases it can be obtained for free through the SUS.
Ilaris is indicated for the treatment of periodic cryopyrin-associated syndromes in adults and children, such as:
In addition, this drug can also be used to treat systemic juvenile idiopathic arthritis in children over 2 years of age who have not had good results with treatment with nonsteroidal anti-inflammatory drugs and systemic corticosteroids.
Ilaris is injected into the fat layer under the skin and can only be administered by a doctor or nurse at the hospital. The dose should be adapted to the problem and weight of the person, being the general guidelines:
The injection should be done every 8 weeks, especially in the treatment of periodic syndromes associated with cryopyrin, during the time recommended by your doctor.
The most common side effects of this drug include fever, sore throat, thrush, dizziness, dizziness, cough, shortness of breath, wheezing, or foot pain.
Ilaris should not be used in children under 2 years of age or in people with hypersensitivity to any of its active components, and should also be used with caution in patients with infections or who have easy infections, as this medicine increases the risk of infections